Non-HIV-related comorbidities and uncontrolled HIV replication are independent factors increasing the odds of hospitalization due to COVID-19 among HIV-positive patients in Poland
暂无分享,去创建一个
M. Parczewski | E. Jabłonowska | M. Bociąga-Jasik | E. Mularska | M. Hlebowicz | A. Olczak | J. Kowalska | M. Witak‐Jêdra | E. Siwak | P. Wasilewski | M. Suchacz | Martyna Lara | A. Wandalowicz | Justyna Stempkowska-Rejek
[1] M. Sadkowska-Todys,et al. Data-driven case fatality rate estimation for the primary lineage of SARS-CoV-2 in Poland , 2022, Methods.
[2] J. Tomažič,et al. National strategies for vaccination against COVID‐19 in people living with HIV in Central and Eastern European region , 2021, HIV medicine.
[3] P. Goryński,et al. Characteristics and Clinical Outcomes of 116,539 Patients Hospitalized with COVID-19—Poland, March–December 2020 , 2021, Viruses.
[4] J. Polańska,et al. Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study , 2021, Journal of inflammation research.
[5] Munn Sann Lye,et al. COVID-19 in People Living with HIV: A Systematic Review and Meta-Analysis , 2021, International journal of environmental research and public health.
[6] V. Chinchilli,et al. Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis , 2021, Scientific Reports.
[7] H. Forman,et al. SARS-CoV-2 Infection Hospitalization Rate and Infection Fatality Rate Among the Non-Congregate Population in Connecticut , 2021, The American Journal of Medicine.
[8] H. Merchant,et al. COVID-19 first anniversary review of cases, hospitalization, and mortality in the UK , 2021, Expert review of respiratory medicine.
[9] David R. Holtgrave,et al. COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State , 2021, JAMA network open.
[10] K. Anastos,et al. Clinical Outcomes and Inflammatory Markers by HIV Serostatus and Viral Suppression in a Large Cohort of Patients Hospitalized With COVID-19. , 2021, Journal of acquired immune deficiency syndromes.
[11] K. Bibbins-Domingo,et al. Excess mortality associated with the COVID-19 pandemic among Californians 18–65 years of age, by occupational sector and occupation: March through November 2020 , 2021, medRxiv.
[12] Kłos,et al. Remdesivir-based therapy improved the recovery of patients with COVID-19 in the multicenter, real-world SARSTer study , 2021 .
[13] J. Pell,et al. Occupation and risk of severe COVID-19: prospective cohort study of 120 075 UK Biobank participants , 2020, Occupational and Environmental Medicine.
[14] P. Glasziou,et al. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: Systematic review and meta-analysis. , 2020, Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada.
[15] Ye Yuan,et al. Clinical challenges in cancer patients with COVID-19: Aging, immunosuppression, and comorbidities , 2020, Aging.
[16] C. Akdis,et al. Risk factors for severe and critically ill COVID‐19 patients: A review , 2020, Allergy.
[17] M. Pawłowska,et al. Remdesivir-based therapy improved recovery of patients with COVID-19 in the SARSTer multicentre, real-world study , 2020, medRxiv.
[18] R. Matulionytė,et al. The characteristics of HIV-positive patients with mild/asymptomatic and moderate/severe course of COVID-19 disease—A report from Central and Eastern Europe , 2020, International Journal of Infectious Diseases.
[19] A. Greenberg,et al. SARS-CoV-2 and HIV: Epidemiology, Treatment, and Lessons Learned from HIV. , 2020, AIDS reviews.
[20] A. Horban,et al. The Case Series of 34 Patients with COVID-19 Diagnosed with HIV Infection from Central and Eastern European Countries – Euroguidelines in Central and Eastern Europe Network Group Data , 2020 .
[21] O. Kirk,et al. 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0 , 2020, HIV medicine.
[22] W. Mcfarland,et al. COVID-19 Among People Living with HIV: A Systematic Review , 2020, AIDS and Behavior.
[23] A. Horban,et al. HIV care in times of the COVID-19 crisis — Where are we now in Central and Eastern Europe? , 2020, International Journal of Infectious Diseases.
[24] M. Bickel,et al. COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients , 2020, Infection.
[25] A. Horban,et al. Long‐term trends in HIV care entry: over 15 years of clinical experience from Poland , 2019, HIV medicine.
[26] E. Sprinz,et al. Comorbidity is more common and occurs earlier in persons living with HIV than in HIV-uninfected matched controls, aged 50 years and older: A cross-sectional study. , 2018, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[27] O. Kirk,et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration , 2014, The Lancet.
[28] W. Witkiewicz,et al. Występowanie nadwagi, otyłości i niedoboru masy ciała u pacjentów zakażonych HIV , 2013 .
[29] S. Pocock,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.
[30] Matthias Egger,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies , 2007, PLoS medicine.